Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
47 Results Found
Department of Labor releases proposed rule on transparency of PBM fee disclosures
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers.
HHS OIG releases bulletin on direct-to-consumer drug sales, RFI on need for regulatory changes
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell prescription drugs to patients with federal health care program coverage at lower costs without violating the Anti-Kickback Statute.
CMS announces drugs selected for third round of drug price negotiations
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.
White House releases health care plan
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts.
CMS releases proposed rules on two drug pricing models
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.
DEA, HHS extend telemedicine waivers through 2026
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver flexibilities for prescribing controlled substances via telemedicine.
CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model, BALANCE, for Medicare Part D and Medicaid beneficiaries.
Administration reaches deals with 9 drug companies to lower drug costs
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid by other developed nations.
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.
U.S. reaches trade agreement with U.K. on drug pricing
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In exchange, the U.K. will increase the net price it pays for new medicines by 25%.